7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Platelet-Rich Fibrin and Its Emerging Therapeutic Benefits for Musculoskeletal Injury Treatment

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          New therapies that accelerate musculoskeletal tissue recovery are highly desirable. Platelet-rich fibrin (PRF) is a leukocyte- and platelet-rich fibrin biomaterial that acts as a binding site for both platelets and growth factors. Through increasing the local concentration of growth factors at specific tissues, PRF promotes tissue regeneration. PRF has been frequently used in combination with bone graft materials to reduce healing times and promote bone regeneration during maxillofacial surgery. However, its benefits during muscle repair and recovery are less well-documented. Here, we perform a narrative review on PRF therapies and muscle injuries to ascertain its beneficial effects. We reviewed the factors that contribute to the biological activity of PRF and the published pre-clinical and clinical evidence to support its emerging use in musculoskeletal therapy. We include in vitro studies, in vivo animal studies and clinical articles highlighting both the success and failures of PRF treatment. PRF can promote the healing process when used in a range of orthopaedic and sports-related injuries. These include cartilage repair, rotator cuff surgery and anterior cruciate ligament surgery. However, conflicting data for these benefits have been reported, most likely due to inconsistencies in both PRF preparation protocols and dosing regimens. Despite this, the literature generally supports the use of PRF as a beneficial adjuvant for a range of chronic muscle, tendon, bone or other soft tissue injuries. Further clinical trials to confirm these benefits require consistency in PRF preparation and the classification of a successful clinical outcome to fully harness its potential.

          Related collections

          Most cited references104

          • Record: found
          • Abstract: found
          • Article: not found

          Platelet-rich plasma: Growth factor enhancement for bone grafts.

          Platelet-rich plasma is an autologous source of platelet-derived growth factor and transforming growth factor beta that is obtained by sequestering and concentrating platelets by gradient density centrifugation. This technique produced a concentration of human platelets of 338% and identified platelet-derived growth factor and transforming growth factor beta within them. Monoclonal antibody assessment of cancellous cellular marrow grafts demonstrated cells that were capable of responding to the growth factors by bearing cell membrane receptors. The additional amounts of these growth factors obtained by adding platelet-rich plasma to grafts evidenced a radiographic maturation rate 1.62 to 2.16 times that of grafts without platelet-rich plasma. As assessed by histomorphometry, there was also a greater bone density in grafts in which platelet-rich plasma was added (74.0% +/- 11%) than in grafts in which platelet-rich plasma was not added (55.1% +/- 8%; p = 0.005).
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part III: leucocyte activation: a new feature for platelet concentrates?

            Platelet-rich fibrin (PRF) belongs to a new generation of platelet concentrates, with simplified processing and without biochemical blood handling. In this third article, we investigate the immune features of this biomaterial. During PRF processing, leucocytes could also secrete cytokines in reaction to the hemostatic and inflammatory phenomena artificially induced in the centrifuged tube. We therefore undertook to quantify 5 significant cell mediators within platelet poor plasma supernatant and PRF clot exudate serum: 3 proinflammatory cytokines (IL-1beta, IL-6, and TNF-alpha), an antiinflammatory cytokine (IL-4), and a key growth promoter of angiogenesis (VEGF). Our data are correlated with that obtained in plasma (nonactivated blood) and in sera (activated blood). These initial analyses revealed that PRF could be an immune regulation node with inflammation retrocontrol abilities. This concept could explain the reduction of postoperative infections when PRF is used as surgical additive.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Comparative release of growth factors from PRP, PRF, and advanced-PRF.

              The use of platelet concentrates has gained increasing awareness in recent years for regenerative procedures in modern dentistry. The aim of the present study was to compare growth factor release over time from platelet-rich plasma (PRP), platelet-rich fibrin (PRF), and a modernized protocol for PRF, advanced-PRF (A-PRF).
                Bookmark

                Author and article information

                Journal
                Medicina (Kaunas)
                medicina
                Medicina
                MDPI
                1010-660X
                1648-9144
                15 May 2019
                May 2019
                : 55
                : 5
                : 141
                Affiliations
                [1 ]University of Medicine and Pharmacy Craiova, 200349 Craiova, Romania; alexandrugrecu@ 123456yahoo.com
                [2 ]Varinor Matériaux SA, CH 2800 Delémont, Switzerland; lucien.reclaru@ 123456varinor.ch
                [3 ]Department of Technology of Materials and 9 Devices in Dental Medicine, “Victor Babes” University of Medicine and Pharmacy from Timisoara, 300041 Timisoara, Romania; lavinia_ardelean@ 123456umft.ro
                [4 ]Department of Oro-Maxilo-Facial Surgery, University of Medicine and Pharmacy Craiova, 200349 Craiova, Romania
                [5 ]Department of Plastic Surgery, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania; meciurea@ 123456gmail.com
                Author notes
                [* ]Correspondence: oliviu.nica@ 123456gmail.com (O.N.); Ciuca.md@ 123456gmail.com (E.M.C.); Tel.: +40-746020496 (O.N.); +40-745158317 (E.M.C.)
                Author information
                https://orcid.org/0000-0001-8489-5937
                https://orcid.org/0000-0003-2694-909X
                Article
                medicina-55-00141
                10.3390/medicina55050141
                6572609
                31096718
                a33e4ef3-a55f-4eb7-a732-62b11239d6e5
                © 2019 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 19 February 2019
                : 23 April 2019
                Categories
                Review

                platelet-rich fibrin,musculoskeletal system,biological therapy,bone regeneration,platelet activation

                Comments

                Comment on this article